

Special Issue

Structure-Based Antiviral Drugs and Vaccine Design

Message from the Guest Editors

This Special Issue aims to promote studies on drug and vaccine design and development against viral diseases using structure-based approaches including AI-powered technologies. Certainly, it is more rational to utilize their structural relations for designs such as between receptors and ligands or antigens and antibodies. In recent years, AI-incorporated structure-based designing programs have significantly enhanced design efficiency and effectiveness. We would like to encourage and publish these data by using innovative technologies in antiviral therapeutics and preventive vaccines. The articles will be included in basic research in vitro, in vivo, and clinical studies.

Guest Editors

Dr. Shi-hua Xiang

School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA

Prof. Dr. Fengwei Bai

Cell and Molecular Biology Program, University of Southern Mississippi, Hattiesburg, MS 39406, USA

Deadline for manuscript submissions

15 December 2025



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/218727

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).